Hyperhidrosis is a medical condition in which the eccrine glands are overactive and produce more sweat than normal to regulate normal body temperature. There are two types of hyperhidrosis namely primary focal hyperhidrosis and secondary (generalized) hyperhidrosis. Primary focal hyperhidrosis generally occurs at multiple locations on the body including axillary, palmar, plantar, trunk/inguinal, craniofacial and it often begins in childhood or adolescence age. Secondary (generalized) hyperhidrosis occur due to excessive sweating caused by medical conditions such as menopause, diabetes, obesity and side effect of medications such as anti-depressants. Hyperhidrosis patients worry about over-sweating causing often other emotional problems including depression, social isolation, and decreased confidence. Atacama Therapeutics, Inc. is in the process of developing TC-5214 in phase II for the treatment of hyperhidrosis.
HYPERHIDROSIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
As of November 2017, the hyperhidrosis therapeutics pipeline comprises 12 drug candidates in different stages of development, with maximum number of active drugs in the Phase II of development.
Some of the players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan, Plc, TheraVida Inc., Atacama Therapeutics, Inc. and others.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles